- Many expensive cancer drugs have unclear patient benefit. New cancer drugs are being launched before their long-term effectiveness for patients can be evaluated. Several years later, most of them still lack scientific evidence for actually increasing life expectancy or improving quality of life. https://link.springer.com/article/10.1007/s40261-023-01285-4 50 comments science
Linked pages
- Annals of Oncology - Journal - Elsevier https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy166/5004443 39 comments
- Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis | The BMJ https://www.bmj.com/lookup/doi/10.1136/bmj.l5221 12 comments